ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer

作者：Gary A. Ulaner, Melvin J. Silverstein, C. Nangia, M. Tetef, Louis Vandermolen, Colleen L. Coleman, Sadia Khan, H. MacDonald, Trushar Patel, T. Techasith, A. Mauguen · 发表于：JAMA Network Open · 年份：2024 · DOI：10.1001/jamanetworkopen.2024.23435 · 被引用次数：19 · 研究领域：Medicine

Key Points Question Does estrogen receptor (ER)–targeted 16α-18F-fluoro-17β-estradiol (FES) positron emission tomography (PET) computed tomography (CT) perform as well as current standard-of-care imaging (SOC) for staging locally advanced breast cancer or evaluating suspected recurrence? Findings In this diagnostic study of 124 patients with ER-positive breast cancer, there was no statistically significant difference between SOC and experimental FES PET/CT for detection of pathologically proven distant metastases or recurrences. Meaning These findings suggest that FES PET/CT could be considered for staging or detection of recurrence in patients with ER-positive breast cancer.